肺痨康对实验性结核小鼠抗结核药物疗效的影响

Research on the Effect of "Fei Laokang" to Other Antitubercular Medicines on Tuberculosis Infected Experimental Mouse

目的:观测肺痨康对结核小鼠化学药物增效解毒作用的影响。方法:人型结核分枝杆菌(H37RV)标准株造模,观测肺小利小剂量组,肺小异小剂量组,肺中利大剂量组,肺中异大剂量组,利福平大、小剂量组,异烟肼大、小剂量组体重、IgG、IFN-γ水平及肝肺组织病理变化。结果:各治疗组小鼠体重均与模型组具有差异(P<0.05);治疗组间,联合组与西药组无显著性差异(P>0.05);肺痨康联合西药组体重下降程度最低,与利福平、异烟肼组比较有差异(P<0.05)。联合组大、小剂量较利福平、异烟肼大、小剂量组均能较明显减轻血浆IFN-γ水平下降(P<0.05)及增加血浆IgG水平(P<0.05)。与西药组比较,肺痨康加西药联合组肝脏多发性坏死病变明显减轻。结论:肺痨康对实验性结核小鼠抗结核疗效有增效减毒的作用。

Objective：Study on the detoxification synergy of＂Fei Laokang＂on tuberculosis infected mouse.Method：we use the H37RV to build up the model to observe the indexes including weight,IgG,IFN-γ,lung tissue and liver tissue pathological change.There are drug groups and combining drug groups which are combined with＂Fei Laokang＂.Combining drug groups include low＂Fei Laokang＂low RFP concentration group,low＂Fei Laokang＂low retozide consentration group,middle＂Fei Laokang＂high RFP concentration group and middle＂Fei Laokang＂high retozide concentration group.Drug groups include low and high RFP concentration group,low and high retozide concentration group.Result：There are difference of weight between each remedy group and model group（P〈0.05）.There are no distinct difference between the Combining drug group and drug group（P〉0.05）.The combining group has the lowest level of weight decrease which has difference between the RFP group and the retozide group（P〈0.05）.Comparing with the low and high concentration group separately,the combining drug group has a more instinct effect on the prevention of the decreasing on blood IFN-γ level（P〈0.05）and on the increasing of the blood IgG level（P〈0.05）to the RFP group and the retozide group.The combining drug group can distinctly alleviate the cases of multiple putrascence in liver.Conclusion：The＂Fei Laokang＂has detoxification synergy during the curing tuberculosis infected experimental mouse.